This article is more than 5 years old. Information may no longer be current.

Specialists more likely to treat ocular toxoplasmosis now than a decade ago

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LOS ANGELES — The number of uveitis specialists who treat all patients with ocular toxoplasmosis, regardless of clinical findings, has almost tripled over the course of a decade, according to results from a physician survey.

All physician members of the American Uveitis Society received written questionnaires; 96 responded. Of those physicians, 79 said they evaluate and manage patients with ocular toxoplasmosis. In 2001, 15% of physician respondents said they treat all cases regardless of clinical findings, compared with 6% of respondents in 1991. The major indications for treatment among other respondents were severe inflammatory responses and proximity of retinal lesions to the fovea and optic disk.

A total of nine drugs were used in 24 different regimens as treatments of choice for typical cases of recurrent toxoplasmic retinochoroiditis, with the combination of pyrimethamine, sulfadiazine and prednisone being the most commonly used regimen (29% of respondents).

Full survey results are published in the July issue of American Journal of Ophthalmology.